SCHEMBL301099

SCHEMBL301099

[CH2]CC(=O)c1ccc(Br)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 3/20 0.64
HDAC1 Q13547 3/20 0.59
HDAC8 Q9BY41 3/20 0.59
HDAC3 O15379 1/20 0.59
HDAC4 P56524 1/20 0.59
HDAC7 Q8WUI4 1/20 0.59
HDAC2 Q92769 1/20 0.59
HDAC10 Q969S8 1/20 0.59
HDAC11 Q96DB2 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59
HDAC9 Q9UKV0 1/20 0.59
HDAC5 Q9UQL6 1/20 0.59
CES2 O00748 1/20 0.54
CES1 P23141 1/20 0.54
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
OGG1 O15527 1/20 0.50
HAO1 Q9UJM8 1/20 0.50
NPC1 O15118 1/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6975979 0.82 GSK3B (0.59) GSK3BHDAC1HDAC8HDAC3HDAC4
SCHEMBL241664 0.80 GSK3B (0.70) GSK3BHDAC1HDAC8HDAC3HDAC4
SCHEMBL1305020 0.80 GSK3B (0.70) GSK3BHDAC1HDAC8HDAC3HDAC4
SCHEMBL6979097 0.79 HDAC1 (0.61) GSK3BHDAC1HDAC8HDAC3HDAC4
SCHEMBL7429718 0.78 NPC1 (0.60) CA1CA2NPC1HPGDRAB9A
SCHEMBL55916 0.78 GSK3B (0.67) GSK3BHDAC1HDAC8HDAC3HDAC4
SCHEMBL3469826 0.78 GSK3B (0.71) GSK3BHDAC1HDAC8HDAC3HDAC4
SCHEMBL28180851 0.78 GSK3B (0.38) GSK3BHDAC1HDAC8HDAC3HDAC4
SCHEMBL70930 0.78 GSK3B (1.00) GSK3BHDAC1HDAC8HDAC3HDAC4
Ethylene SCHEMBL11738819 0.77 GSK3B (0.59) GSK3BHDAC1HDAC8HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110078717-A One kind double benzofurans-benzimidazole salt compound with anti-tumor activity and preparation method thereof 红河学院 2019-08-02 CN claimed
EP-1192141-A1 1,4-DIAZACYCLOHEPTANE DERIVATIVES AS NEUROPROTECTIVE AGENTS AstraZeneca UK Limited (GB) 2002-04-03 EP claimed
WO-2000078736-A1 1,4-DIAZACYCLOHEPTANE DERIVATIVES AS NEUROPROTECTIVE AGENTS ASTRAZENECA UK LIMITED (GB) 2000-12-28 WO claimed
EP-2610248-B1 METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND TEIJIN PHARMA LTD (JP) 2016-06-08 EP disclosed
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
US-8952174-B2 Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst TEIJIN PHARMA LIMITED (JP) 2015-02-10 US disclosed
US-8916714-B2 Method for producing phenyl-substituted heterocyclic derivative by means of coupling method using palladium compound TEIJIN PHARMA LIMITED (JP) 2014-12-23 US disclosed
EP-2610248-A1 METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND Teijin Pharma Limited (JP) 2013-07-03 EP disclosed
US-20130158272-A1 METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND TEIJIN PHARMA LIMITED (JP) 2013-06-20 US disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
EP-1192141-A1 1,4-DIAZACYCLOHEPTANE DERIVATIVES AS NEUROPROTECTIVE AGENTS AstraZeneca UK Limited (GB) 2002-04-03 EP disclosed
WO-2000078736-A1 1,4-DIAZACYCLOHEPTANE DERIVATIVES AS NEUROPROTECTIVE AGENTS ASTRAZENECA UK LIMITED (GB) 2000-12-28 WO disclosed
CN-1118138-A Substituted azolone derivatives for treating diseases caused by helicobacter JANSSEN PHARMACEUTICA NV (BE) 1996-03-06 CN disclosed
US-4025558-A SPIRO(CYCLOHEXANE-1,1*(2'H)-NAPHTHALENE); BENZOSPIRAN DERIVATIVES; CNS DEPRESSANTS, LOWERS BLOOD PRESSURE THE UPJOHN COMPANY (US) 1977-05-24 US disclosed
US-4010201-A AMINOBENZOSPIRANS, CENTRAL NERVOUS SYSTEM DEPRESSANT, HYPOTENSIVE THE UPJOHN COMPANY (US) 1977-03-01 US disclosed
US-3979444-A CENTRAL NERVOUS SYSTEM DEPRESSANTS, HYPOTENSIVES THE UPJOHN COMPANY (US) 1976-09-07 US disclosed
US-3953425-A Azepine indanyl and tetralin butyrophenones THE UPJOHN COMPANY (US) 1976-04-27 US disclosed
US-3932425-A CNS DEPRESSANT, BLOOD PRESSURE LOWERING THE UPJOHN COMPANY (US) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158272-A1 METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND XDH, AOC1, PAH GSK3B 3972/4885HDAC1 1578/4885HDAC8 3784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.